Free Trial

Adaptive Biotechnologies Q3 2023 Earnings Report

Adaptive Biotechnologies logo
$7.45 -0.22 (-2.87%)
As of 12:44 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Adaptive Biotechnologies EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.32
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Adaptive Biotechnologies Revenue Results

Actual Revenue
$37.92 million
Expected Revenue
$43.26 million
Beat/Miss
Missed by -$5.34 million
YoY Revenue Growth
N/A

Adaptive Biotechnologies Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

Adaptive Biotechnologies Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Adaptive Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adaptive Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptive Biotechnologies and other key companies, straight to your email.

About Adaptive Biotechnologies

Adaptive Biotechnologies (NASDAQ:ADPT), a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

View Adaptive Biotechnologies Profile

More Earnings Resources from MarketBeat